Amgen Inc. (AMGN) Earnings Call Analysis
NASDAQ · Healthcare · Drug Manufacturers - General
Next earnings call: 2026-08-04
(Q2 2026)
— full calendar
Earnings Reports
-
Amgen (AMGN) Q2 2025: Volume Surges 13% as 15 Brands Deliver Double-Digit Growth
June 16, 2026
-
Amgen (AMGN) Q4 2025: 13 Products Drive Double-Digit Growth as Rare Disease Tops $5B
June 15, 2026
-
Amgen (AMGN) Q1 2026: Growth Drivers Power 24% Surge, Pipeline and AI Initiatives Set New Paradigm
May 01, 2026
-
Amgen (AMGN) Q3 2025: Volume Growth Hits 14% as 16 Drugs Post Double-Digit Gains
November 05, 2025
-
Amgen (AMGN) Q1 2025: 14% Volume Surge Drives 35% Biosimilars Growth, Pipeline Execution Accelerates
June 30, 2025
-
Amgen (AMGN) Q3 2024: Pipeline-Driven R&D Spend Rises 35% as Meritide, Rare Disease, and Biosimilars Expand Growth Levers
October 30, 2024
-
Amgen (AMGN) Q2 2024: Rare Disease Revenue Tops $1.1B, Pipeline Investment Reshapes Margin Outlook
August 06, 2024
-
Amgen (AMGN) Q1 2024: Rare Disease Sales Top $950M as Meritide Phase III Plans Accelerate
May 02, 2024
-
Amgen (AMGN) Q4 2023: Horizon Adds $954M, Rare Disease Now 4th Growth Pillar
February 06, 2024